Ticker: ATOS

Atossa Therapeutics, Inc. (NASDAQ: ATOS) Quick read: the company is a clinical‑stage biopharma advancing oral (Z)-endoxifen. It has encouraging clinical signals across multiple trials but is still pre‑revenue, burning cash, facing patent challenges and a Nasdaq minimum‑bid compliance notice. Key ...